Literature DB >> 24894947

[Risk factor management of coronary heart disease : what is evidence-based?].

E B Winzer1, G C Schuler.   

Abstract

In patients with coronary heart disease the further course of the disease can be substantially influenced by means of a targeted treatment of risk factors. A reduction of hospital referrals, an improvement in quality of life and an extension in life expectation by secondary prophylactic measures have been well documented. In addition to an optimized medicinal therapy, an often drastic change in lifestyle with a focus on a consistent abstinence from nicotine, a healthy diet and regular physical exercise is necessary. Data from healthcare research show that these targets are only insufficiently achieved. The implementation of current guidelines should therefore be rigorously applied. There is a need for research particularly with respect to the prognostic significance of beta blocker therapy for patients with stable coronary heart disease and preserved left ventricular function, the prognostic significance of targeted weight loss for overweight or obese coronary heart disease patients, the effectiveness of psychosocial interventions in the various patient groups and their implementation into routine care. Research is also necessary with respect to optimization of structured rehabilitation programs and improvement in patient compliance.

Entities:  

Mesh:

Year:  2014        PMID: 24894947     DOI: 10.1007/s00059-014-4108-z

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  39 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  Dose response between physical activity and risk of coronary heart disease: a meta-analysis.

Authors:  Jacob Sattelmair; Jeremy Pertman; Eric L Ding; Harold W Kohl; William Haskell; I-Min Lee
Journal:  Circulation       Date:  2011-08-01       Impact factor: 29.690

3.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

Authors: 
Journal:  Arch Intern Med       Date:  2001-02-12

4.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

5.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.

Authors:  Kornelia Kotseva; David Wood; Guy De Backer; Dirk De Bacquer; Kalevi Pyörälä; Ulrich Keil
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2009-04

6.  β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.

Authors:  Neiko Ozasa; Takeshi Morimoto; Bingyuan Bao; Yutaka Furukawa; Yoshihisa Nakagawa; Kazushige Kadota; Masashi Iwabuchi; Satoshi Shizuta; Hiroki Shiomi; Junichi Tazaki; Masahiro Natsuaki; Takeshi Kimura
Journal:  Int J Cardiol       Date:  2012-11-02       Impact factor: 4.164

7.  Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.

Authors:  Nancy A Rigotti; Andrew L Pipe; Neal L Benowitz; Carmen Arteaga; Dahlia Garza; Serena Tonstad
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

Review 8.  Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.

Authors:  David Preiss; Naveed Sattar
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

Review 9.  Exercise for type 2 diabetes mellitus.

Authors:  D E Thomas; E J Elliott; G A Naughton
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

10.  Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease.

Authors:  Falk Müller-Riemenschneider; Kathrin Damm; Charlotte Meinhard; Angelina Bockelbrink; Christoph Vauth; Stefan N Willich; Wolfgang Greiner
Journal:  GMS Health Technol Assess       Date:  2009-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.